- Stereotactic body radiotherapy (SBRT) offered significantly better OS than percutaneous image-guided local tumor ablation (LTA) in patients with inoperable early-stage NSCLC.
Why this matters
- This study contradicts previous research that found no significant difference in survival with SBRT vs LTA.
- 15,792 patients with inoperable early-stage NSCLC from the National Cancer Database who received SBRT (n=14,651) or LTA (n=1141).
- Median follow-up, 26.2 months.
- Funding: NIH.
- SBRT offered a lower mortality risk compared with LTA in the unadjusted cohort (HR, 0.86; P<.001 and after propensity score weighting p=".002).</li">
- Adjusted rates of OS for SBRT vs LTA, respectively:
- 1 year: 87.5% vs 83.5%.
- 2 years: 68.0% vs 63.0%.
- 3 years: 52.2% vs 45.9%.
- 5 years: 31.0% vs 26.2%.
- In the propensity score-weighted group, SBRT offered lower mortality risk than LTA for tumor sizes >2.0 cm (HR, 0.72; P<.001 but there was no significant difference between sbrt and lta for tumor sizes cm.>
- Retrospective design.